Investigational drug · Phase 2
BI 1815368
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Macular Edema.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "BI 1815368"
First trial start
2025
Jun 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 1815368", any sponsor or status.
Conditions studied
As listed on its trial records.
- Macular Edema
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 1815368" as an intervention, largest first.
- A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular EdemaPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06962839 · 300 participants (planned) · Start Jun 5, 2025 · Primary completion Mar 1, 2028
Drug: BI 1815368; Placebo · For: Macular Edema
Sites: Phoenix, Arizona; Arcadia, California; Huntington Beach, California · 98 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT05337592 · 72 participants · Start Jun 14, 2022 · Primary completion Oct 18, 2022
Drug: BI 1815368 formulation 1; Placebo and 1 more · For: Healthy
Sites: Biberach, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT05857878 · 59 participants · Start Jun 23, 2023 · Primary completion Jun 6, 2024
Drug: BI 1815368; Matching placebo · For: Healthy
Sites: Edegem, Belgium
Boehringer IngelheimBoehringer Ingelheim
NCT06494774 · 26 participants · Start Aug 19, 2024 · Primary completion Nov 13, 2024
Drug: BI 1815368; Placebo matching BI 1815368 · For: Healthy
Sites: Tokyo, Sumida-ku, Japan
- A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the BodyCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06655220 · 14 participants · Start Nov 8, 2024 · Primary completion Dec 8, 2024
Drug: Metformin hydrochloride; BI 1815368 · For: Healthy
Sites: Biberach, Germany
- A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1815368 in the BloodCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05965583 · 14 participants · Start Aug 2, 2023 · Primary completion Oct 24, 2023
Drug: BI 1815368; Itraconazole · For: Healthy
Sites: Biberach, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT07693218 · 8 participants · Start Jul 16, 2026 · Primary completion Aug 29, 2026
Drug: BI 1815368 (C-14); BI 1815368 (C-13) · For: Healthy
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Macular Edema
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- KIO-104Phase 21 trial
Kiora Pharmaceuticals, Inc. · Macular Edema
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.